Healthy individuals.
Conditions
Interventions
Intervention 1: Treatment group: In this group
capsules with 250 mg Tanacetum parthenium (L) Sch are administrated 1 time per day for 2 weeks. Intervention 2: control group: In this group
capsules with 250 mg corn flour are administrated 1 time per day for 2 weeks.
Sponsors
Vice chancellor for research, Fasa University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: age between20 and 60 negative hx of D.M negative hx of major surgery(Under 6 months) negative hx of HTN negative hx of coagulopathy like hemophilia negative hx of liver diseases Satisfaction to participate in the scheme. not use anticoaglant drugs and anti inflamatory drugs such as NSAIDs Not to have bleeding disorders in GI system
Exclusion criteria
Exclusion criteria: positive hx of coagulopathy like hemophilia positive hx of HTN positive hx of major surgery(Under 6 months) positive hx of D.M liver disease such as cirihosis or hepatitis Age over 60 or under the age of 20 use anticoaglant drugs and anti inflamatory drugs such as NSAIDs Dissatisfaction to participate in the scheme To have bleeding disorders in GI system possible complications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prothrombin Time (PT). Timepoint: At the beginning of intervention, 2 weeks and 6 weeks after the beginning of intervention. Method of measurement: Venous Blood Test.;Partial Thromboplastin Time (PTT). Timepoint: At the beginning of intervention, 2 weeks and 6 weeks after the beginning of intervention. Method of measurement: Venous Blood Test.;IL-1ß. Timepoint: At the beginning of intervention and 2weeks later. Method of measurement: Venous Blood Test.;IFN-a. Timepoint: At the beginning of intervention and 2weeks later. Method of measurement: Venous Blood Test.;IFN-?. Timepoint: At the beginning of intervention and 2 weeks later. Method of measurement: Venous Blood Test.;TNF-a. Timepoint: At the beginning of intervention and 2 weeks later. Method of measurement: Venous Blood Test.;Monocyte chemotactic protein-1. Timepoint: At the beginning of intervention and 2 weeks later. Method of measurement: Venous Blood Test.;IL-6. Timepoint: At the beginning of intervention and 2 weeks later. Method of measurement: Venous Blood Test.;IL-8. Timepoint: At the beginning of intervention and 2 weeks later. Method of measurement: Venous Blood Test.;IL-10. Timepoint: At the beginning of intervention and 2 weeks later. Method of measurement: Venous Blood Test.;IL-12p70. Timepoint: At the beginning of intervention and 2 weeks later. Method of measurement: Venous Blood Test.;IL-17A. Timepoint: At the beginning of intervention and 2 weeks later. Method of measurement: Venous Blood Test.;IL-18. Timepoint: At the beginning of intervention and 2 weeks later. Method of measurement: Venous Blood Test.;IL-23. Timepoint: At the beginning of intervention and 2 weeks later. Method of measurement: Venous Blood Test.;IL-33. Timepoint: At the beginning of intervention and 2 weeks later. Method of measurement: Venous Blood Test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Satisfaction of patients. Timepoint: 1 month after recruitment. Method of measurement: visual analog scale.;Tolerance. Timepoint: 1 month after recruitment. Method of measurement: visual analog scale.;Drug side effects. Timepoint: 1 month after recruitment. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactEbrahim Akrami
Fasa University of Medical Sciences
Outcome results
None listed